1. Home
  2. WLFC vs SYRE Comparison

WLFC vs SYRE Comparison

Compare WLFC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLFC
  • SYRE
  • Stock Information
  • Founded
  • WLFC 1985
  • SYRE 2013
  • Country
  • WLFC United States
  • SYRE United States
  • Employees
  • WLFC N/A
  • SYRE N/A
  • Industry
  • WLFC Industrial Specialties
  • SYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • WLFC Consumer Discretionary
  • SYRE Health Care
  • Exchange
  • WLFC Nasdaq
  • SYRE Nasdaq
  • Market Cap
  • WLFC 1.3B
  • SYRE 1.2B
  • IPO Year
  • WLFC 1996
  • SYRE 2016
  • Fundamental
  • Price
  • WLFC $158.83
  • SYRE $17.94
  • Analyst Decision
  • WLFC
  • SYRE Strong Buy
  • Analyst Count
  • WLFC 0
  • SYRE 8
  • Target Price
  • WLFC N/A
  • SYRE $51.50
  • AVG Volume (30 Days)
  • WLFC 46.0K
  • SYRE 664.6K
  • Earning Date
  • WLFC 03-10-2025
  • SYRE 05-08-2025
  • Dividend Yield
  • WLFC 0.63%
  • SYRE N/A
  • EPS Growth
  • WLFC 146.23
  • SYRE N/A
  • EPS
  • WLFC 15.34
  • SYRE N/A
  • Revenue
  • WLFC $557,540,000.00
  • SYRE N/A
  • Revenue This Year
  • WLFC $1.70
  • SYRE N/A
  • Revenue Next Year
  • WLFC $13.55
  • SYRE N/A
  • P/E Ratio
  • WLFC $10.93
  • SYRE N/A
  • Revenue Growth
  • WLFC 36.04
  • SYRE N/A
  • 52 Week Low
  • WLFC $48.10
  • SYRE $16.71
  • 52 Week High
  • WLFC $235.43
  • SYRE $40.84
  • Technical
  • Relative Strength Index (RSI)
  • WLFC 39.77
  • SYRE 43.06
  • Support Level
  • WLFC $180.01
  • SYRE $16.71
  • Resistance Level
  • WLFC $189.95
  • SYRE $19.50
  • Average True Range (ATR)
  • WLFC 9.71
  • SYRE 1.28
  • MACD
  • WLFC -0.22
  • SYRE 0.07
  • Stochastic Oscillator
  • WLFC 49.23
  • SYRE 42.86

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: